Developer docs
API playgroundTry for free, no card

Search company profiles

Hinge Bio

Full company profile

uuid00002me

Namestring
Hinge Bio
Legal namestring
Hinge Bio, Inc.
Websiteurl
hingebio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Hinge Bio, Inc. is a privately held, clinical-stage biotechnology company founded in 2021 and headquartered in Redwood City, California. The company develops multivalent, multispecific antibody-based therapeutics using its proprietary GEM-DIMER™ platform, which enables combination of multiple fully active antigen-binding fragments into a single molecule with cooperative binding for enhanced biological activity.

Its lead program, HB2198, is a dual CD19/CD20-targeting antibody with dual Fc domains designed to achieve deep (>99%) B cell depletion for an immune reset in B cell-mediated autoimmune disorders, initially Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The company highlights a differentiated safety profile versus CAR-T and T cell engagers, achieved through immune effector engagement without T cell activation. The FDA cleared the HB2198 IND in October 2025, and Hinge Bio initiated two Phase 1 trials—with the first subject dosed in April 2026.

Hinge Bio is pre-revenue and operates a partnership-based business model, generating value through upfront licensing fees, development and sales milestones, and future royalties from regional commercialization partners. Its first commercial agreement, with Kyorin Pharmaceutical (September 2025), covers development and commercialization of HB2198 in Japan, with Hinge Bio retaining global (ex-Japan) rights. The company was financed by a $30 million Series A in January 2025 led by Point72, alongside Ridgeback Capital, InVivium Capital, and Lightswitch Capital.

Short descriptiontext

Hinge Bio is a clinical-stage biotechnology company developing multivalent, multispecific antibody therapeutics via its proprietary GEM-DIMER platform. Its lead program, HB2198, targets CD19 and CD20 to deeply deplete B cells in autoimmune diseases such as SLE and Lupus Nephritis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlingame, United States
HQ citystring
Burlingame
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody therapeutics, B cell depletion therapies, multispecific antibody platform, autoimmune disease therapeutics, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bispecific Antibody Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Pre-revenue biotech company expecting to generate revenue through licensing deals, upfront payments, and milestone payments from pharmaceutical partners. The Kyorin collaboration includes $10 million upfront and up to $95 million in milestone payments for SLE indication plus additional payments for other indications.

hingebio.com
2Sales Royalties
TypeLicensing Royalties
Description

Royalty payments from commercialization partners on net sales of approved therapeutics. The Kyorin deal includes tiered sales royalties for HB2198 sales in Japan.

hingebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Hinge Bio is a privately-held, clinical-stage biotechnology company that leverages its proprietary GEM-DIMER™ platform to design and develop multivalent, multispecific antibody-based therapeutics. Its lead product candidate, HB2198, is a dual CD19/CD20-targeting B cell-depleting agent with enhanced immune effector engagement, intended to achieve deep (>99%) B cell depletion and immune reset in B cell-mediated autoimmune diseases such as Systemic Lupus Erythematosus and Lupus Nephritis. The company develops drug candidates through clinical stages and partners with larger pharmaceutical companies for regional commercialization, currently demonstrated by its license and collaboration with Kyorin Pharmaceutical for Japan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • >99% B cell depletion demonstrated in preclinical in vivo studies
+2 more records
Product overview1 text field

Hinge Bio is a biotechnology company leveraging its proprietary GEM-DIMER™ platform to develop the next generation of multivalent, multispecific antibody-based therapeutics. The company's lead product candidate is HB2198, a B cell-depleting agent designed for autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The GEM-DIMER platform enables the creation of therapeutics that combine multiple fully-active antibodies into single molecules with enhanced biological activity, while HB2198 represents the first clinical-stage program emerging from this platform, targeting both CD19 and CD20 with dual Fc domains for superior immune effector cell engagement.

Product and service2 records
1GEM-DIMER™ Platform
CategoryProprietary Antibody Engineering Platform
Description

A proprietary technology platform that creates multivalent, multispecific antibody-based therapeutics designed to bind targets cooperatively for enhanced biological activity and unique functionality. The platform enables combining multiple fully-active antibodies into a single molecule with entirely new functionality for superior safety and efficacy.

2HB2198
CategoryB cell-Depleting Antibody Therapeutic
Description

A novel B cell-depleting therapy targeting both CD19 and CD20 with enhanced dual Fc domains for enhanced immune effector cell engagement. Designed to achieve rapid and deep (>99%) depletion of B cells to reset the immune system in B cell-mediated autoimmune disorders such as Systemic Lupus Erythematosus (SLE) and Lupus Nephritis, without the challenges and toxicities associated with CAR-T or T cell Engagers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

License and collaboration agreement for development and commercialization of HB2198 in Japan for multiple autoimmune indications starting with Systemic Lupus Erythematosus. Hinge Bio receives $10 million upfront and is eligible for up to $95 million in milestone payments for SLE indication plus additional payments for other indications. Kyorin funds development, regulatory, marketing and commercialization activities in Japan and contributes to global development. Joint Steering Committee established.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing cell-based and in vivo gene therapy approaches for autoimmune disease, including deep B cell depletion strategies. CMO Paul Brunetta previously led autoimmune development at Sana — a direct precedent for the type of therapy HB2198 competes with.

TypeDirect peer
Description

Clinical-stage biotech developing T cell engagers and multispecific antibodies (acquired by Merck for $680M). Hinge Bio's VP of CMC previously led CMC at Harpoon — a direct comparator for the multispecific antibody development model and platform-company exit pathway.

TypeBroad incumbent
Description

Developer of the leading anti-CD20 franchise (rituximab, ocrelizumab, obinutuzumab) which Hinge Bio explicitly aims to displace in autoimmune disease. Also operates broad multispecific antibody R&D. CMO Paul Brunetta was previously Global Head of Anti-CD20 at Genentech.

TypeBroad incumbent
Description

Large incumbent with bispecific antibody platform (linvoseltamab, odronextamab) and deep CD20 franchise (rituximab partnership via Sanofi historically). Directly relevant as a bispecific/multispecific antibody developer and autoimmune competitor to Hinge Bio's GEM-DIMER approach.

TypeDirect peer
Description

Clinical-stage biotech developing CAR-T therapies (e.g., CABA-201) for B cell-mediated autoimmune diseases including SLE and lupus nephritis. Same indication focus and immune-reset thesis as HB2198, via a cell therapy modality.

TypeEmerging player
Description

Clinical-stage biotech with a proprietary bispecific antibody platform (CTX-009, CTX-112) targeting oncology indications. Comparable multispecific antibody platform developer at similar clinical stage to Hinge Bio.

TypeDirect peer
Description

Clinical-stage biotech with proprietary multispecific antibody platforms (Azymetric, EFECT) developing bispecific therapeutics for cancer and autoimmune indications. Directly comparable as a multispecific antibody platform company at similar development stage.

TypeRegional player
Description

Japanese pharmaceutical company that licensed HB2198 for Japan development and commercialization. Acts as both a regional commercialization partner and an industry peer in autoimmune disease drug development across Asian markets.

TypeEmerging player
Description

Clinical-stage company developing a portfolio of oncology and immunology therapeutics including multispecific antibodies (e.g., CLN-978). Comparable as a multispecific antibody developer with a diversified pipeline rather than a single-asset focus.

TypeDirect peer
Description

Clinical-stage company developing CAR-T cell therapies for autoimmune diseases including lupus. Directly competes with Hinge Bio's B cell depletion thesis in lupus, though via a CAR-T modality rather than an off-the-shelf antibody.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hinge Bio

Bispecific Antibody Therapeuticshingebio.com

Hinge Bio is a clinical-stage biotechnology company developing multivalent, multispecific antibody therapeutics via its proprietary GEM-DIMER platform. Its lead program, HB2198, targets CD19 and CD20 to deeply deplete B cells in autoimmune diseases such as SLE and Lupus Nephritis.

What Hinge Bio does

Hinge Bio, Inc. is a privately held, clinical-stage biotechnology company founded in 2021 and headquartered in Redwood City, California. The company develops multivalent, multispecific antibody-based therapeutics using its proprietary GEM-DIMER™ platform, which enables combination of multiple fully active antigen-binding fragments into a single molecule with cooperative binding for enhanced biological activity.

Its lead program, HB2198, is a dual CD19/CD20-targeting antibody with dual Fc domains designed to achieve deep (>99%) B cell depletion for an immune reset in B cell-mediated autoimmune disorders, initially Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The company highlights a differentiated safety profile versus CAR-T and T cell engagers, achieved through immune effector engagement without T cell activation. The FDA cleared the HB2198 IND in October 2025, and Hinge Bio initiated two Phase 1 trials—with the first subject dosed in April 2026.

Hinge Bio is pre-revenue and operates a partnership-based business model, generating value through upfront licensing fees, development and sales milestones, and future royalties from regional commercialization partners. Its first commercial agreement, with Kyorin Pharmaceutical (September 2025), covers development and commercialization of HB2198 in Japan, with Hinge Bio retaining global (ex-Japan) rights. The company was financed by a $30 million Series A in January 2025 led by Point72, alongside Ridgeback Capital, InVivium Capital, and Lightswitch Capital.

Hinge Bio firmographics

Firmographics
Name
Hinge Bio
Legal name
Hinge Bio, Inc.
Website
https://hingebio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Hinge Bio is a clinical-stage biotechnology company developing multivalent, multispecific antibody therapeutics via its proprietary GEM-DIMER platform. Its lead program, HB2198, targets CD19 and CD20 to deeply deplete B cells in autoimmune diseases such as SLE and Lupus Nephritis.
Ownership category
akta.pro rank

Hinge Bio industry classification

Industry
Product category
Bispecific Antibody Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Bispecific antibody therapeutics
  • B cell depletion therapies
  • Multispecific antibody platform
  • Autoimmune disease therapeutics
  • Clinical-stage biotechnology

Where Hinge Bio is headquartered

Location

Headquarters

HQ city
Burlingame
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Hinge Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Pre-revenue biotech company expecting to generate revenue through licensing deals, upfront payments, and milestone payments from pharmaceutical partners. The Kyorin collaboration includes $10 million upfront and up to $95 million in milestone payments for SLE indication plus additional payments for other indications.
  2. Sales Royalties: Royalty payments from commercialization partners on net sales of approved therapeutics. The Kyorin deal includes tiered sales royalties for HB2198 sales in Japan.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Hinge Bio product offering

Product offering

Core offering

Hinge Bio is a privately-held, clinical-stage biotechnology company that leverages its proprietary GEM-DIMER™ platform to design and develop multivalent, multispecific antibody-based therapeutics. Its lead product candidate, HB2198, is a dual CD19/CD20-targeting B cell-depleting agent with enhanced immune effector engagement, intended to achieve deep (>99%) B cell depletion and immune reset in B cell-mediated autoimmune diseases such as Systemic Lupus Erythematosus and Lupus Nephritis. The company develops drug candidates through clinical stages and partners with larger pharmaceutical companies for regional commercialization, currently demonstrated by its license and collaboration with Kyorin Pharmaceutical for Japan.

Product overview

Hinge Bio is a biotechnology company leveraging its proprietary GEM-DIMER™ platform to develop the next generation of multivalent, multispecific antibody-based therapeutics. The company's lead product candidate is HB2198, a B cell-depleting agent designed for autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The GEM-DIMER platform enables the creation of therapeutics that combine multiple fully-active antibodies into single molecules with enhanced biological activity, while HB2198 represents the first clinical-stage program emerging from this platform, targeting both CD19 and CD20 with dual Fc domains for superior immune effector cell engagement.

Differentiator

Problem solved

Functional benefit

Products and services

  • GEM-DIMER™ Platform A proprietary technology platform that creates multivalent, multispecific antibody-based therapeutics designed to bind targets cooperatively for enhanced biological activity and unique functionality. The platform enables combining multiple fully-active antibodies into a single molecule with entirely new functionality for superior safety and efficacy.
  • HB2198 A novel B cell-depleting therapy targeting both CD19 and CD20 with enhanced dual Fc domains for enhanced immune effector cell engagement. Designed to achieve rapid and deep (>99%) depletion of B cells to reset the immune system in B cell-mediated autoimmune disorders such as Systemic Lupus Erythematosus (SLE) and Lupus Nephritis, without the challenges and toxicities associated with CAR-T or T cell Engagers.

Quantifiable outcome

  • >99% B cell depletion demonstrated in preclinical in vivo studies
  • +2 more outcomes

Companies that use Hinge Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Hinge Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Hinge Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kyorin Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 30 September 2025License and collaboration agreement for development and commercialization of HB2198 in Japan for multiple autoimmune indications starting with Systemic Lupus Erythematosus. Hinge Bio receives $10 million upfront and is eligible for up to $95 million in milestone payments for SLE indication plus additional payments for other indications. Kyorin funds development, regulatory, marketing and commercialization activities in Japan and contributes to global development. Joint Steering Committee established.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Hinge Bio competitors and assessment

Company assessment

Direct peers

  • Sana Biotechnology: Clinical-stage biotech developing cell-based and in vivo gene therapy approaches for autoimmune disease, including deep B cell depletion strategies. CMO Paul Brunetta previously led autoimmune development at Sana — a direct precedent for the type of therapy HB2198 competes with.
  • Harpoon Therapeutics (Merck): Clinical-stage biotech developing T cell engagers and multispecific antibodies (acquired by Merck for $680M). Hinge Bio's VP of CMC previously led CMC at Harpoon — a direct comparator for the multispecific antibody development model and platform-company exit pathway.
  • Cabaletta Bio: Clinical-stage biotech developing CAR-T therapies (e.g., CABA-201) for B cell-mediated autoimmune diseases including SLE and lupus nephritis. Same indication focus and immune-reset thesis as HB2198, via a cell therapy modality.
  • Zymeworks: Clinical-stage biotech with proprietary multispecific antibody platforms (Azymetric, EFECT) developing bispecific therapeutics for cancer and autoimmune indications. Directly comparable as a multispecific antibody platform company at similar development stage.
  • Kyverna Therapeutics: Clinical-stage company developing CAR-T cell therapies for autoimmune diseases including lupus. Directly competes with Hinge Bio's B cell depletion thesis in lupus, though via a CAR-T modality rather than an off-the-shelf antibody.

Broad incumbents

  • Genentech (Roche): Developer of the leading anti-CD20 franchise (rituximab, ocrelizumab, obinutuzumab) which Hinge Bio explicitly aims to displace in autoimmune disease. Also operates broad multispecific antibody R&D. CMO Paul Brunetta was previously Global Head of Anti-CD20 at Genentech.
  • Regeneron Pharmaceuticals: Large incumbent with bispecific antibody platform (linvoseltamab, odronextamab) and deep CD20 franchise (rituximab partnership via Sanofi historically). Directly relevant as a bispecific/multispecific antibody developer and autoimmune competitor to Hinge Bio's GEM-DIMER approach.

Emerging players

  • Compass Therapeutics: Clinical-stage biotech with a proprietary bispecific antibody platform (CTX-009, CTX-112) targeting oncology indications. Comparable multispecific antibody platform developer at similar clinical stage to Hinge Bio.
  • Cullinan Oncology: Clinical-stage company developing a portfolio of oncology and immunology therapeutics including multispecific antibodies (e.g., CLN-978). Comparable as a multispecific antibody developer with a diversified pipeline rather than a single-asset focus.

Regional players

  • Kyorin Pharmaceutical: Japanese pharmaceutical company that licensed HB2198 for Japan development and commercialization. Acts as both a regional commercialization partner and an industry peer in autoimmune disease drug development across Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Hinge Bio social profiles

Digital presence

Hinge Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hinge Bio leadership team

Management profile

Number of profiles

Profiles8 records

Hinge Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hinge Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hinge Bio

What does Hinge Bio do?

Hinge Bio is a privately-held, clinical-stage biotechnology company that leverages its proprietary GEM-DIMER™ platform to design and develop multivalent, multispecific antibody-based therapeutics. Its lead product candidate, HB2198, is a dual CD19/CD20-targeting B cell-depleting agent with enhanced immune effector engagement, intended to achieve deep (>99%) B cell depletion and immune reset in B cell-mediated autoimmune diseases such as Systemic Lupus Erythematosus and Lupus Nephritis. The company develops drug candidates through clinical stages and partners with larger pharmaceutical companies for regional commercialization, currently demonstrated by its license and collaboration with Kyorin Pharmaceutical for Japan.

Is Hinge Bio a public or private company?

Hinge Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hinge Bio founded?

Hinge Bio was founded in 2021. It employs 11 to 50 people.

Where is Hinge Bio based?

Hinge Bio is headquartered in Burlingame, United States, in the North America region.

How does Hinge Bio make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are sales Royalties.

Who are Hinge Bio's main competitors?

Direct peers on record are Sana Biotechnology, Harpoon Therapeutics (Merck), Cabaletta Bio, Zymeworks and Kyverna Therapeutics. Broad incumbents are Genentech (Roche) and Regeneron Pharmaceuticals. Emerging players are Compass Therapeutics and Cullinan Oncology. Kyorin Pharmaceutical is listed as a regional player.

Does Hinge Bio have an API?

No public API is recorded for Hinge Bio.

What industry is Hinge Bio in?

Hinge Bio's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus NephritisHinge Bio, Inc. announced that the FDA has cleared its Investigational New Drug application for HB2198, a novel B cell-depleting therapy targeting both CD19 and CD20, enabling the company to initiate a Phase 1 clinical trial in patients with Systemic Lupus Erythematosus and Lupus Nephritis. The drug candidate, developed on Hinge Bio's GEM-DIMER platform, demonstrated potent and durable depletion of B cells in preclinical studies, with the therapeutic goal of achieving an immune system reset. The company expects to open the clinical trial in the fourth quarter of 2025.FierceBiotechKyorin pens $105M pact for Japan rights to Hinge's preclinical lupus drugKyorin Pharmaceutical agreed to pay $105 million for the Japanese rights to Hinge Bio's preclinical lupus drug, HB2198, including a $10 million upfront payment and up to $95 million in milestone payments. The deal also requires Kyorin to contribute to the global development of the therapy, which targets B-cell depletion using Hinge's GEM-DIMER platform.Pulse 2.0Hinge Bio: $30 Million (Series A) To Develop Therapies For Autoimmune DiseaseHinge Bio closed a $30 million Series A financing round led by Point72, with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital. The funds will support the entry of its lead candidate HB2198 into Phase 1 clinical trials for Systemic Lupus Erythematosus in 2025 and further development of its GEM-DIMER platform. This investment aims to advance therapies targeting B cell-mediated autoimmune disorders through enhanced natural killer cell engagement.citybizHinge Bio Raises $30M Series AHinge Bio raised $30M in Series A funding led by Point72, with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital. The company will use the funds to advance its lead product candidate HB2198 into a Phase 1 clinical trial for Systemic Lupus Erythematosus and develop additional therapeutics from its GEM-DIMER platform.FinSMEsHinge Bio Raises $30M in Series A FinancingHinge Bio raised $30M in Series A funding led by Point72, with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital. The company will use the funds to advance its lead product candidate HB2198 into a Phase 1 clinical trial for Systemic Lupus Erythematosus and develop additional therapeutics from its GEM-DIMER platform.VC News DailyHinge Bio Scores $30 Million Series AHinge Bio, Inc., a privately-held biotechnology company headquartered in Burlingame, California, announced the close of a $30 million Series A financing round. The round was led by Point72 with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital. The funding will support the company's ongoing research and development initiatives in the biotechnology sector.GlobeNewswireHinge Bio, Inc. Chief Scientific Officer, Daniel Capon, Ph.D., to Present its GEM-DIMER™ Platform Technology at the University of Oxford, Kennedy Institute of Rheumatology’s Annual Translational ReseaHinge Bio's Chief Scientific Officer Daniel Capon will present the company's GEM-DIMER platform at the Kennedy Institute of Rheumatology's annual conference in Oxford on August 29, 2024. The technology creates cooperative-binding antibody topologies, and its lead candidate HB2198 targets CD19, CD20, and Fc receptors for autoimmune diseases.PR NewswireJuha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development OfficerHinge Bio, Inc., a privately-held biotechnology company based in Burlingame, California, announced the appointment of Dr. Juha Punnonen as Chief Development Officer. Dr. Punnonen brings over 20 years of biopharmaceutical executive experience in oncology and immuno-oncology, having previously held senior roles at Ascendis Pharma and Merck & Co., Inc. He will lead the preclinical and clinical development strategy for the company's GEM-DIMER™ technology platform, which generates multivalent, multispecific antibody-based therapeutics.BioSpaceHinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical DevelopmentHinge Bio appointed Barry Selick as CEO and Carin Rollins as COO, with Joshua Carle as Chief Business Officer, to drive its GEM-DIMER programs toward clinical development. The company, focused on oncology, aims to advance its multivalent antibody platform into product candidates.